Novartis to acquire Avidity Biosciences for $12 billion
PositiveFinancial Markets

Novartis has announced its plans to acquire Avidity Biosciences for a staggering $12 billion, marking a significant move in the biopharmaceutical industry. This acquisition is expected to enhance Novartis's portfolio in innovative therapies, particularly in the field of RNA-targeted treatments. The deal highlights Novartis's commitment to expanding its capabilities and addressing unmet medical needs, which could lead to groundbreaking advancements in patient care.
— Curated by the World Pulse Now AI Editorial System









